Two favoured Crohn's surgery techniques performed the same in a head-to-head trial

Two surgical techniques promoted in recent years as ways to keep Crohn's disease from coming back after bowel surgery worked no better than each other in a randomised trial — and both left about a third of patients with disease visible on endoscopy within six months [s1][s2]. The result, from the Italian REMEASURE trial, is a useful corrective to enthusiasm that had outpaced the evidence for both approaches [s1].

Crohn's disease often forces surgery to remove an inflamed segment of bowel, most commonly where the small intestine meets the colon, but the disease has a habit of returning at the join, and recurrence after that first operation is common enough that many patients face repeat surgery over a lifetime [s1]. That is why surgeons have searched for technical tweaks that might blunt the odds of the disease coming back [s1]. Two ideas have gained traction for preventing that. One is the Kono-S anastomosis, a way of reconnecting the bowel that aims to keep the new join wide and supported. The other is resecting more of the mesentery — the fatty, blood-vessel-rich tissue that tethers the gut — on the theory that it harbours inflammation that seeds recurrence [s1]. Both have been championed on the strength of observational data; REMEASURE put them directly against each other [s1].

What the trial did

REMEASURE was a prospective, randomised, controlled trial at a single tertiary referral hospital [s1][s2]. Seventy-three patients undergoing a first ileocolic resection for Crohn's disease were randomly assigned to one of the two techniques: 36 to a Kono-S anastomosis and 37 to mesenteric resection with a conventional functional end-to-end anastomosis [s1]. The primary endpoint was endoscopic recurrence at six months, defined as a Rutgeerts score of i2 or greater — a standard endoscopic grading of how much disease has returned at the surgical join [s1]. Secondary endpoints included postoperative complications and clinical, endoscopic and surgical recurrence tracked out to 24 months [s1].

What it found

The two groups looked almost identical. The perioperative course was similar, and surgical recurrence over follow-up was rare and evenly split — just two patients, one in each arm [s1]. On the primary endpoint, endoscopic recurrence at six months occurred in 12 of 36 Kono-S patients (33%) and 12 of 37 mesenteric-resection patients (32%) [s1]. Time-to-event estimates at 6, 12 and 18 months showed no significant differences in endoscopic or clinical recurrence between the techniques [s1]. In a statistical model of what predicted later recurrence, a perforating disease phenotype stood out as a risk factor for late endoscopic recurrence (hazard ratio 1.70, P=0.05) — a reminder that the biology of a patient's disease may matter more than the fine details of how the bowel is sewn back together [s1]. The trial's bottom line was unambiguous: neither technique conferred a significant advantage in complications or in surgical, endoscopic or clinical recurrence [s1].

How to read it

A null result like this is easy to undervalue, but it does real work. Both Kono-S and extended mesenteric resection had been promoted partly on mechanistic appeal and partly on uncontrolled series that cannot separate the technique from the patients who happened to receive it [s1]. A randomised comparison, even a small one, is a stronger test — and here it found nothing to choose between them [s1]. That matters clinically, because mesenteric resection is a more extensive operation, and if it does not reduce recurrence, the added surgery is hard to justify on that basis alone [s1].

The caveats run the other way from the usual pattern. This is a small, single-centre trial, so it could have missed a modest real difference — absence of a significant effect is not proof the techniques are identical [s1]. But the near-superimposable recurrence rates, 33% against 32%, do not hint at a hidden benefit waiting for a bigger study to reveal; if anything they argue that the choice between these techniques is not where the leverage over recurrence lies [s1].

What to watch

The finding that a perforating phenotype predicted recurrence points to where the field may get more traction — matching the aggressiveness of medical therapy after surgery to a patient's disease biology, rather than searching for the perfect stitch [s1]. Larger multicentre trials could firm up whether either technique helps specific subgroups, but REMEASURE suggests the broad answer is that, on their own, they do not [s1][s2].

This article describes research and is not medical advice. Surgical decisions in Crohn's disease are for patients and their surgical teams.

Sources

• REMEASURE: mesenteric resection vs Kono-S anastomosis in Crohn's disease — Updates in Surgery, 26 June 2026
• The Remeasure Trial, NCT07164209 — ClinicalTrials.gov